BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315I

Known as: BCR-ABL1 T315I Mutation, BCR-ABL Thr315Ile Mutation, BCR/ABL Fusion Protein with T315I 
A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.944C>T mutation. This protein is comprised of the N-terminus of the… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
BACKGROUND Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the… (More)
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
In chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, tyrosine kinase inhibitor (TKI… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
An international basis for comparison of BCR-ABL mRNA levels is required for the common interpretation of data derived from… (More)
  • table 1
  • table 2
  • figure 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Individualized PCR strategies hamper comparability of molecular results between different laboratories in several fields of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Patients with advanced stages of chronic myeloid leukemia (CML) often manifest imatinib mesylate resistance associated with point… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Mutations within the BCR-ABL kinase domain in imatinib-treated chronic myeloid leukemia (CML) are the main mechanism of acquired… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
For the diagnosis of CML and for monitoring of treatment response the detection of the t(9;22)(q34;q11) or the BCR-ABL… (More)
  • table 2
  • figure 1
  • table 3
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
STI-571, a new Abl tyrosine kinase inhibitor recently approved by the Food and Drug Administration, is highly effective in… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
We report that mutation in the gene for plectin, a cytoskeleton–membrane anchorage protein, is a cause of autosomal recessive… (More)
Is this relevant?